DIAGAST, French biotech company ensuring transfusion safety, among worldwide leaders in Immunohematology solutions, is pleased to announce the appointment of Olivier Brolli as new Chief Executive Officer (CEO).
Olivier brings up a rich managerial and sales experience in both In Vitro Diagnostic (IVD) and Information Technology (IT) fields to DIAGAST. He took up his position on August, 23rd 2021.
His professional background
Olivier has also a great experience of Sales and Marketing in big IT companies such as Dell Services (Sales Director in Health Care, from 2010 to 2012) and Alcatel Lucent (Regional Director of key accounts and businesses, from 2004 to 2008). Besides, he was Key account Director for the United Nations in Geneva and New York, from 2001 to 2003. Olivier is 52 years old and is a graduate of EM Lyon and ESSEC Business School.
“I am delighted and honored to join DIAGAST, a French Biotech company with high potential, that operates worldwide in the Blood Transfusion sector. I am looking forward to supporting the company growth – together with all the teams – and exploring new attractive market opportunities”, says Olivier Brolli.
Because receiving blood is receiving life, transfusion should be completely safe everywhere. DIAGAST revolutionized the Immunohematology field in 2004 by magnetizing red blood cells thanks to its breakthrough E.M.® Technology and continues to innovate all around the world. Our teams support biologists and blood banks for making rapid and optimal decisions, so that the patients have a safe blood transfusion.
Built on our unique cell heritage, our diagnostic solutions, either manual or automated, are associated with our high-performance lab software. They allow to enhance patients’ outcome and also increase organizational efficiency while reducing costs for laboratories.
Therefore, DIAGAST goes hand in hand with laboratories to shape the future while facing new challenges.